In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Impact of age on clinical outcomes after PCI in patients with ACS and stable CAD treated with 23-month ticagrelor monotherapy following 1-month DAPT in the randomized GLOBAL LEADERS study

Session Poster Session 3

Speaker Mariusz Tomaniak

Event : ESC Congress 2019

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardiovascular Disease in the Elderly
  • Session type : Poster Session

Authors : M Tomaniak (Rotterdam,NL), P Chichareon (Amsterdam,NL), R Modolo (Amsterdam,NL), P Buszman (Katowice,PL), M Sabate (Barcelona,ES), T Geisler (Tübingen,DE), C Hamm (Giessen,DE), PG Steg (Paris,FR), Y Onuma (Rotterdam,NL), P Vranckx (Hasselt,BE), M Valgimigli (Bern,CH), S Windecker (Bern,CH), R Anderson (Cardiff,GB), M Dominici (Terni,IT), PW Serruys (London,GB)

M Tomaniak1 , P Chichareon2 , R Modolo2 , P Buszman3 , M Sabate4 , T Geisler5 , C Hamm6 , PG Steg7 , Y Onuma8 , P Vranckx9 , M Valgimigli10 , S Windecker10 , R Anderson11 , M Dominici12 , PW Serruys13 , 1Erasmus Medical Centre, ThoraxCenter - Rotterdam - Netherlands (The) , 2Academic Medical Center - Amsterdam - Netherlands (The) , 3Medical University of Silesia - Katowice - Poland , 4Clinic Hospital Barcelona - Barcelona - Spain , 5Uniklinikum Tübingen - Tübingen - Germany , 6University of Giessen - Giessen - Germany , 7FACT (French Alliance for Cardiovascular Trials), Université Paris Diderot, Hôpital Bichat - Paris - France , 8Erasmus University Medical Centre - Rotterdam - Netherlands (The) , 9Hartcentrum Hasselt, Jessa Ziekenhuis - Hasselt - Belgium , 10Bern University Hospital, Inselspital, University of Bern - Bern - Switzerland , 11University Hospital of Wales - Cardiff - United Kingdom of Great Britain & Northern Ireland , 12Azienda Ospedaliera S. Maria - Terni - Italy , 13NHLI, Imperial College London, London - London - United Kingdom of Great Britain & Northern Ireland ,




The efficacy and safety of ticagrelor monotherapy in elderly patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) or stable coronary artery disease (CAD) has not been evaluated.


To evaluate the efficacy and safety of ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) after PCI in relation to age and clinical presentation in the GLOBAL LEADERS study cohort.


This is a subanalysis of the randomized multicentre GLOBAL LEADERS study, comparing the experimental strategy of 23-month ticagrelor monotherapy after 1 month of ticagrelor and aspirin with the reference strategy of 12-month DAPT followed by 12-month aspirin monotherapy in 15991 patients undergoing PCI. Patients were categorized into elderly and very elderly according to a pre-specified cut-off of 75 years and a post-hoc defined cut-off of 80 years. Impact of age and clinical presentation (ACS versus stable CAD) on clinical outcome at 2 years was evaluated. The primary endpoint was a composite of all-cause mortality or nonfatal, centrally adjudicated, new Q-wave myocardial infarction. 


In the overall elderly (>75 years) population (n=2565), primary endpoint occurred in 7.2% of patients in the experimental group and in 9.4% of patients in the reference group (p=0.041) at 2 years (p int =0.23). Elderly patients in the experimental group had a lower rate of definite stent thrombosis (ST) (0.2% vs. 0.9%, p=0.043, p int=0.03), definite or probable ST (0.4 vs. 1.3%, p=0.015, p int=0.01) and a numerically higher rates of BARC 3 or 5 type bleeding (5.0% vs. 3.9%, p=0.192, p int=0.06), when compared to the reference arm.

Among elderly patients presenting with ACS both treatment groups did not differ in the rates of primary endpoint (9.1% vs. 10.8%, p=0.367) and BARC 3 or 5 type bleeding (4.7% vs. 5.7%, p=0.458), whereas among elderly patients with stable CAD the experimental strategy was associated with numerically lower rates of the primary endpoint (5.7% vs. 8.4%, p=0.046) (p int =0.42) and a higher rate of BARC 3 or 5 type bleedings (5.3% vs. 2.6%, p=0.012) (p int =0.02) at 2 years.

Exploratory analyses among very elderly (=80 years) patients (n=1169) indicated no significant differences between treatment groups in the rates of the primary endpoint (10.2% vs. 11.7% p=0.411, p int=0.940) and BARC 3 or 5 type bleeding (6.0% vs. 5.3%, p=0.630, p int=0.514) at 2 years.  

The efficacy and safety of the experimental treatment strategy of 23-month ticagrelor monotherapy after 1-month DAPT following PCI was not identified as age-dependent. Among elderly patients the anti-ischemic benefit was derived at the expense of increased rate of BARC 3 or 5 type bleeding in stable CAD subgroup, but not in ACS subgroup.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are